Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TRXB with free AI briefings, catalyst countdowns, and dilution alerts.

TRXB · TRex Bio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$90.9M Cash on Hand
23.6mo Cash Runway
Follow TRXB by email Get an email when TRXB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TRXB, unsubscribe in one click. Privacy

📣 What TRXB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
TRB-061 Moderate-to-severe Atopic Dermatitis Phase 1 · NCT06934252 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TRXB holds $90.9M in cash and short-term investments and burns about $11.6M/quarter from operations, an estimated runway of 23.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TRXB files for a raise →

👥 Who Owns TRXB

Insiders 36% Other 5%+ holders 18.6% Institutions (4 holders) 31.7% Public and other holders 13.7%
HolderTypeShares% of sharesAs of
LILLY & Co ELI
10% owner
Insider 5,480,872 19.04% 2026-10-13
SVLSF VI, LLC
10% owner
Insider 3,011,818 10.46% 2026-10-08
PFIZER INC. (13-5315170) 5%+ holder (13G) 1,965,066 6.83% 2026-10-08
SV Biotech Crossover Opportunities Fund 5%+ holder (13D) 1,920,667 6.67% 2026-10-08
Johnson & Johnson Innovation - JJDC, Inc 5%+ holder (13G) 1,475,302 5.12% 2026-10-13
Alexandria Venture Investments, LLC
10% owner
Insider 1,346,501 4.68% 2026-10-13
Carol Giltner Gallagher
Director · +17,500 options
Insider 251,471 0.87% 2026-10-08
Laura Berner
Chief Operating Officer
Insider 168,574 0.59% 2026-10-08
Joel S Marcus
Director · +17,500 options
Insider 41,871 0.15% 2026-10-13
Peter Hirth
Director · +17,500 options
Insider 38,202 0.13% 2026-10-08
Ali Zarrin
Chief Scientific Officer
Insider 18,111 0.06% 2026-10-08

Share count 28,788,654 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TRXB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRXB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.